To evaluate safety and performance of Drug Eluting Stent and Bare Metal Stent in the treatment of patients with coronary artery blockage.

A retrospective, observational, real-world, safety and performance evaluation of DES and BMS for coronary artery lesions.

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2017/11/010531

Enrollment

2000

Registered

2017-11-16

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I251- Atherosclerotic heart disease of native coronary artery

Interventions

Intervention1: OSUMâ?¢ and Metaforâ?¢: OSUMâ?¢ -Cobalt Chromium Coronary Stent System Metaforâ?¢ Sirolimus-Eluting Coronary Stent System Control Intervention1: NIL: NIL

Sponsors

Meril Life Sciences Pvt Ltd

Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients who have been treated with OSUM• and/or Metafor•. 2. Patients who are contactable, willing to participate will be taken into the study by signing voluntary informed consent form.

Exclusion criteria

Exclusion criteria: 1. There are no exclusion criteria for this study.

Design outcomes

Primary

Measure	Time frame
Major Adverse Cardiac Events (MACE)Timepoint: In-Hospital, 1 month, 6 months, 12 months and 24 months	—

Secondary

Measure	Time frame
1. Target vessel failure (TVF) 2. Stent Thrombosis (Definite, possible, and Probable) Rate as Defined by Academic Research Consortium (ARC)Timepoint: 1. 1 month, 6 months, 12 months and 24 months 2. In-Hospital, 1 month, 6 months, 12 months and 24 months	—

Countries

India

Contacts

Public ContactDr Ashok Thakkar

Meril Life Sciences Pvt Ltd

ashok.thakkar@merillife.com9879443584

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026